https://repositorio.ufba.br/handle/ri/40786
Campo DC | Valor | Idioma |
---|---|---|
dc.creator | Gomes, Tarcisio Santana | - |
dc.date.accessioned | 2024-12-18T10:35:31Z | - |
dc.date.available | 2025-10-04 | - |
dc.date.available | 2024-12-18T10:35:31Z | - |
dc.date.issued | 2024-10-04 | - |
dc.identifier.citation | GOMES, Tarcísio Santana. Saúde muscular em pacientes portadores de doença renal crônica não dialítica: marcadores clínicos nutricionais e de qualidade de vida. 2024. 128 f. Tese (Doutorado em Alimentos, Nutrição e Saúde) - Escola de Nutrição, Universidade Federal da Bahia, Salvador, 2024. | pt_BR |
dc.identifier.uri | https://repositorio.ufba.br/handle/ri/40786 | - |
dc.description.abstract | The progression of chronic kidney disease is accompanied by multiple nutritional and metabolic abnormalities, which can compromise renal function, affecting the clinical and nutritional status of these patients. Among the nutritional alterations, sarcopenia and dynapenia stand out, terms used to designate a reduction in muscle mass, muscle strength and physical performance. OBJECTIVES: To identify the association of muscle quality markers with clinical, nutritional and quality of life aspects in patients with non-dialytic chronic kidney disease. METHODS: This is a cross-sectional study conducted from January to September 2012 with patients with CKD stages 3 to 5 (stage 5 non-dialysis) who were followed at the Nutrition and Nephropathy Outpatient Clinic of the Professor Francisco de Magalhães Neto Outpatient Clinic. Adult patients (20 and <60 years) and elderly patients (≥60 years), of both sexes, with creatinine clearance between 89 and 15 ml/min/1.73m², participated in this study. Anthropometric, body composition, muscle strength, biochemical and quality of life indicators were evaluated. RESULTS: The results presented allow us to conclude that sarcopenia and dynapenia are prevalent in patients with CKD-ND and that, according to the review performed, they are prognostic of severity, including mortality. It is worth noting that muscle health indicators were associated with quality of life domains related to physical health in this population. In addition, it was observed that the phase angle and HGS measurement can be indicators to assess muscle quality in these patients. CONCLUSION: our studies reinforce the importance of monitoring nutritional indicators associated with muscle quality in order to reduce possible clinical and nutritional complications and the impact on quality of life in patients with non-dialysis-dependent chronic kidney disease. | pt_BR |
dc.description.sponsorship | Fundação de Amparo à Pesquisa do Estado da Bahia (FAPESB) | pt_BR |
dc.language | por | pt_BR |
dc.publisher | Universidade Federal da Bahia | pt_BR |
dc.rights | Acesso Restrito/Embargado | pt_BR |
dc.subject | Doença renal crônica | pt_BR |
dc.subject | Insuficiência renal crônica | pt_BR |
dc.subject | Sarcopenia | pt_BR |
dc.subject | Dinapenia | pt_BR |
dc.subject | Força muscular | pt_BR |
dc.subject | Estado nutricional | pt_BR |
dc.subject | Biomarcadores | pt_BR |
dc.subject | Qualidade de vida | pt_BR |
dc.subject.other | Chronic kidney disease | pt_BR |
dc.subject.other | Renal Insufficiency, Chronic | pt_BR |
dc.subject.other | Sarcopenia | pt_BR |
dc.subject.other | Dynapenia | pt_BR |
dc.subject.other | Muscle Strength | pt_BR |
dc.subject.other | Nutritional Status | pt_BR |
dc.subject.other | Biomarkers | pt_BR |
dc.subject.other | Quality of life | pt_BR |
dc.title | Saúde muscular em pacientes portadores de doença renal crônica não dialítica: marcadores clínicos nutricionais e de qualidade de vida | pt_BR |
dc.title.alternative | Muscle health in patients with non-dialysis chronic kidney disease: nutritional and quality of life clinical markers | pt_BR |
dc.type | Tese | pt_BR |
dc.publisher.program | Programa de Pós-Graduação em Alimentos, Nutrição e Saúde (PGNUT) | pt_BR |
dc.publisher.initials | UFBA | pt_BR |
dc.publisher.country | Brasil | pt_BR |
dc.subject.cnpq | CNPQ::CIENCIAS DA SAUDE::NUTRICAO::ANALISE NUTRICIONAL DE POPULACAO | pt_BR |
dc.contributor.advisor1 | Medeiros, Jairza Maria Barreto | - |
dc.contributor.advisor1ID | https://orcid.org/0000-0003-3533-7108 | pt_BR |
dc.contributor.advisor1Lattes | http://lattes.cnpq.br/6674302443921098 | pt_BR |
dc.contributor.advisor-co1 | Gusmão, Maria Helena Lima | - |
dc.contributor.advisor-co1Lattes | http://lattes.cnpq.br/8259934776295622 | pt_BR |
dc.contributor.referee1 | Gusmão, Maria Helena Lima | - |
dc.contributor.referee1Lattes | http://lattes.cnpq.br/8259934776295622 | pt_BR |
dc.contributor.referee2 | Jesus, Rosângela Passos de | - |
dc.contributor.referee2Lattes | http://lattes.cnpq.br/2925811144406467 | pt_BR |
dc.contributor.referee3 | Costa, Carlos Alberto Soares da | - |
dc.contributor.referee3ID | https://orcid.org/0000-0001-8302-657X | pt_BR |
dc.contributor.referee3Lattes | http://lattes.cnpq.br/8701554187772246 | pt_BR |
dc.contributor.referee4 | Burbano, Erika Vanesa Cadena | - |
dc.contributor.referee4Lattes | http://lattes.cnpq.br/7448213015063969 | pt_BR |
dc.contributor.referee5 | Cardozo, Ludmila Ferreira Medeiros de França | - |
dc.contributor.referee5ID | https://orcid.org/0000-0001-8507-2369 | pt_BR |
dc.contributor.referee5Lattes | http://lattes.cnpq.br/2547887546741044 | pt_BR |
dc.creator.ID | https://orcid.org/0000-0002-1817-2834 | pt_BR |
dc.creator.Lattes | http://lattes.cnpq.br/6346206363371233 | pt_BR |
dc.description.resumo | A progressão da doença renal crônica é acompanhada por múltiplas anormalidades nutricionais e metabólicas, as quais podem comprometer a função renal, afetando o quadro clínico e nutricional desses pacientes. Entre as alterações nutricionais, destacam-se a sarcopenia e a dinapenia, termos utilizados para designar redução da massa muscular, da força muscular e do desempenho físico. OBJETIVOS: Identificar a associação entre marcadores de qualidade muscular com aspectos clínicos nutricionais e de qualidade de vida em pacientes com doença renal crônica não-dialítica. MÉTODOS: Trata-se de um estudo transversal realizado no período de janeiro a setembro de 2012 com pacientes com diagnóstico de DRC, estágios 3 a 5 (estágio 5 não-dialítica), acompanhados no ambulatório de Nutrição e Nefropatias do Ambulatório Professor Francisco de Magalhães Neto. Participaram deste estudo pacientes adultos (20 e < 60 anos) e idosos (≥ 60anos), de ambos os sexos, que possuíam Clearance de Creatinina entre 89 a 15 ml/min/1,73m2. Foram avaliados indicadores antropométricos, de composição corporal, de força muscular, bioquímicos e de qualidade de vida. RESULTADOS: Os resultados apresentados permitem concluir que a sarcopenia e dinapenia são prevalentes em pacientes com DRC-ND e que, de acordo com a revisão realizada, são prognóstico de gravidade, incluindo a mortalidade. Vale ressaltar, que os indicadores de saúde muscular foram associados com domínios de qualidade de vida relacionados à saúde física nesta população. Além disso, observou-se que o ângulo de fase e a medida de FPM podem ser indicadores para avaliar a qualidade muscular nesses pacientes. CONCLUSÃO: nossos estudos reforçam a importância do acompanhamento dos indicadores nutricionais associados a qualidade muscular com o objetivo de reduzir possíveis complicações clínicas, nutricionais e do impacto em qualidade de vida em pacientes com doença renal crônica não dependente de diálise. | pt_BR |
dc.publisher.department | Escola de Nutrição | pt_BR |
dc.relation.references | 1. Gujral UP; Jagannathan R; Ele S. et al. Association between varying cut-points of intermediate hyperglycemia and risk of mortality, cardiovascular events and chronic kidney disease: a systematic review and meta-analysis. BMJ Open Diabetes Res Care. 2021 Apr;9(1): e001776. 2. Karimi E; Bitarafan S; Mousavi SM eta al. The effect of vitamin D supplementation on fibroblast growth factor-23 in patients with chronic kidney disease: A systematic review and meta-analysis. Phytother Res. 2021 Oct;35(10):5339-5351. 3. Rashid I; Sahu G; Tiwari P. et al. Malnutrition as a potential predictor of mortality in chronic kidney disease patients on dialysis: A systematic review and metaanalysis. Clinical Nutrition. 10.1016/j.clnu.2024.05.037. 2024: 3;43(7):1760-1769. doi: 4. Han Q; Zhang R; Wu J. et al. Cross-sectional Relationship Between Dietary Protein Intake, Energy Intake and Protein Energy Wasting in Chronic Kidney Disease Patients. Br J Nutr. 2024 May 31:1-18. doi: 10.1017/S000711452400104 5. Duarte MP; Almeida LS; Neri SGR et al. Prevalence of sarcopenia in patients with chronic kidney disease: a global systematic review and meta-analysis. J Cachexia Sarcopenia Muscle. 2024 Apr;15(2): 501-512.doi: 10.1002/jcsm.13425. 6. Hussein H; Apetrii M; Covic A. Health-related quality of life in patients with chronic kidney disease. Expert Review of Pharmacoeconomics & Outcomes Research. Volume 21, 2021. doi: 10.1080/14737167.2021.1854091 7. Martino FK; Zattarin A; Cinquini C. et al. Low-Protein Diet in Elderly Patients with Chronic Kidney Disease Stage 4 and 5 in Conservative Management: Focus on Sarcopenia Development. 10.3390/nu16101498. Nutrients. 2024:16;16(10):1498. doi: 8. Xiong Y; Jiang X; Zhong Q. et al. Possible sarcopenia and risk of chronic kidney disease: a four-year follow-up study and Mendelian randomization analysis. Endocr Res. 2024: 13:1-14. doi: 10.1080/07435800.2024.2353842. 9. Yildirim S; Colak T; Bayraktar N. et al. Evaluation of Dynapenia and Sarcopenia and Their Associations With Serum Insulin-Like Growth Factor-1 Levels in Renal Transplant Recipients. J Ren Nutr. 2022; 32(3):354-362. 109 doi: 10.1053/j.jrn.2021.08.013 10. Do-Youn Lee; Sunghoon Shin. Association between Chronic Kidney Disease and Dynapenia in Elderly Koreans. Healthcare (Basel). 2023: 17;11(22):2976. doi: 10.3390/healthcare11222976. 11. Shivam Sharma; Darpan Kalra; Ishfaq Rashid et al. Assessment of Health-Related Quality of Life in Chronic Kidney Disease Patients: A Hospital-Based CrossSectional Study. Medicina (Kaunas). 2023 Oct; 59(10): 1788. 12. Nadia E; Alami E Hassani; Mohamed-Amine Akrichi; Habiba Bajit; Chakib Alem. Investigation of accordance between nutritional assessment tools, and bioelectrical impedance-derived phase angle, with the global leadership initiative on malnutrition criteria in hemodialysis patients. Clin Nutr ESPEN. 2024 Jun 6:62:260-269. doi: 10.1016/j.clnesp.2024.05.027. 13. Troutman AD; Arroyo E; Sheridan EM. et al. Skeletal muscle atrophy in clinical and preclinical models of chronic kidney disease: A systematic review and metaanalysis. J Cachexia Sarcopenia Muscle. 2024; 15(1): 21–35. 14. KDOQI. The National Kidney Foundation's Kidney Disease Outcomes Quality Initiative (KDOQI) Grant Initiative: moving clinical practice forward. Am J Kidney Dis. 2010 Mar;55(3):411-4. doi: 10.1053/j.ajkd.2009.11.001 15. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney International (2024) 105 (Suppl 4S), S117S314. 16. Foster MC; Hwang SJ; Larson MG et al. Overweight, obesity, and the development of stage 3 CKD: the Framingham Heart Study. Am J Kidney Dis. 2008;52(1):39-48. 17. Stenvinkel P. Obesity-a disease with many aetiologies disguised in the same oversized phenotype: has the overeating theory failed? Nephrol Dial Transplant 2014. 18. Lu JL; Kalantar-Zadeh K; Ma JZ; et al. Association of body mass index with outcomes in patients with CKD. J Am Soc Nephrol.,2014; 25: 2088–2096. 19. Han Q; Zhang R; Wu J et al. Cross-sectional Relationship Between Dietary Protein Intake, Energy Intake and Protein Energy Wasting in Chronic Kidney Disease Patients. Br J Nutr. 2024: 31:1-18. doi: 10.1017/S0007114524001041. 110 20. Shakhshir MH; Vanoh D; Hassan M; Zyoud SH et al. Mapping the global research landscape on malnutrition for patients with chronic kidney disease: a visualization analysis. J Health Popul Nutr. 2023 Sep 23;42(1):101. doi: 10.1186/s41043-02300445-8. 21. Yamaguchi M; Sugiyama H; Asai A et al. Clinical Impact of Malnutrition According to the Global Leadership Initiative on Malnutrition Criteria Combined With Kidney Dysfunction to Determine Mortality in Inpatients. J Ren Nutr. 2024: 16: S1051-2276(24)00062-1. doi: 10.1053/j.jrn.2024.03.010. 22. Hori M; Takahashi H; Kondo C. et al. Association between Serum 25Hydroxyvitamin D Levels and Sarcopenia in Patients Undergoing Chronic Haemodialysis. Am J Nephrol. 2024;55(3):399-405. doi: 10.1159/000536582. 23. Mathur V; Reaven NL; Funk SE et al. Association of metabolic acidosis with fractures, falls, protein-calorie malnutrition and failure to thrive in patients with chronic kidney disease. Clin Kidney J. 2022 Mar 4;15(7):1379-1386. doi: 10.1093/ckj/sfac065. 24. Helper OE; Qasim H; Tiosano S et al. Physical fitness is an independent predictor of chronic kidney disease development in apparently healthy individuals. J Nephrol. 2024 Jun 13. doi: 10.1007/s40620-024-01966-z. 25. Rosenberg IH. Symposium: sarcopenia: diagnosis and mechanisms sarcopenia: origins and clinical relevance. J Nutr, 127 (1997), pp. 990-991. 26. Evans WJ; Campbell WW. Sarcopenia and age-related changes in body composition and functional capacity. J Nutr. 1993 Feb;123(2 Suppl):465-8. doi: 10.1093/jn/123.suppl_2.465. 27. G. Bahat, A. Tufan, C. Kilic, M.A. Karan, A.J. Cruz-Jentoft. Prevalence of sarcopenia and its components in community-dwelling outpatient older adults and their relation with functionality. Aging Male, 23 (2021), pp. 424-430. 28. A.J. Cruz-Jentoft, G. Bahat, J. Bauer, Y. Boirie, O. Bruyère, T. Cederholm, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing, 48 (2019), pp. 16-31. 29. Sabatino A; Cuppari L; Stenvinkel P; Lindholm B; Avesani CM. Sarcopenia in chronic kidney disease: what have we learned so far? J Nephrol, 34 (2021), pp. 1347-1372. 111 30. Chatzipetrou V; Bégin MJ; Hars M; Trombetti A. Sarcopenia in chronic kidney disease: a scoping review of prevalence, risk factors, association with outcomes, and treatment. Calcif Tissue Int (2021). 31. Ribeiro HS; Neri SGR, Oliveira JS. Association between sarcopenia and clinical outcomes in chronic kidney disease patients: A systematic review and metaanalysis. Clin Nutr. 2022;41(5):1131-1140. doi: 10.1016/j.clnu.2022.03.025. 32. Wathanavasin W; Banjongjit A; Avihingsanon Y. et al. Prevalence of Sarcopenia and Its Impact on Cardiovascular Events and Mortality among Dialysis Patients: A Systematic Review and Meta-Analysis. Nutrients. 2022; 14(19): 4077. 33. Troutman AD; Arroyo E; Sheridan Em et al. Skeletal muscle atrophy in clinical and preclinical models of chronic kidney disease: A systematic review and metaanalysis. J Cachexia Sarcopenia Muscle. 2024; 15(1): 21–35. 34. Amorim GJ; Calado CKM; Oliveira BCS et al. Sarcopenia in Non-Dialysis Chronic Kidney Disease Patients: Prevalence and Associated Factors. Front Med (Lausanne). 2022. Apr 7;9. 35. Caldiroli L; Armelloni S; Eskander A. et al. Association between the uremic toxins indoxyl-sulfate and p-cresyl-sulfate with sarcopenia and malnutrition in elderly patients with advanced chronic kidney disease. Exp Gerontol. 2021: 1;147. 36. Chen X; Zhu X; Han P. et al. Sarcopenia is associated with mild-to-moderate chronic kidney disease in Chinese community-dwelling older men but not in women. Journal of International Medical Research. 2022: 1;50(11). 37. D’alessandro C; Piccoli GB; Barsotti M. et al. Prevalence and correlates of sarcopenia among elderly CKD outpatients on tertiary care. Nutrients. 2018: 10;10(12). 38. Fernandes JFR; Barreto Silva MI; Loivos CP. et al. Obstructive sleep apnea in non-dialyzed chronic kidney disease patients: Association with body adiposity and sarcopenia. Nutrition. 2018: 1; 57:282–9. 39. Ishikawa S; Naito S; Iimori S. et al. Loop diuretics are associated with greater risk of sarcopenia in patients with non-dialysis-dependent chronic kidney disease. PLoS One. 2018: 1;13(2). 40. An JN; Kim JK; Lee HS; Kim SG; Kim HJ; Song YR. Late stage 3 chronic kidney disease is an independent risk factor for sarcopenia, but not proteinuria. Sci Rep. 2021:1;11(1). 112 41. Kusunoki H; Tsuji S; Kusukawa T. et al. Relationships between cystatin C- and creatinine-based eGFR in Japanese rural community- dwelling older adults with sarcopenia. Clin Exp Nephrol. 2021: 1;25(3):231–9. 42. Lee SM, Han MY, Kim SH et al. Indoxyl Sulfate Might Play a Role in Sarcopenia, While Myostatin Is an Indicator of Muscle Mass in Patients with Chronic Kidney Disease: Analysis from the RECOVERY Study. Toxins (Basel). 2022: 1;14(10). 43. Montenegro J; Klein MRST; Bregman R; Prado CM; Barreto Silva MI. Osteosarcopenia in patients with non-dialysis dependent chronic kidney disease. Clinical Nutrition. 2022 Jun 1;41(6):1218–27. 44. Moreno-Gonzalez R; Corbella X; Mattace-Raso F et al. Prevalence of sarcopenia in community-dwelling older adults using the updated EWGSOP2 definition according to kidney function and albuminuria. BMC Geriatr. 2020: 2;20. 45. Cha R Hui; Kang SH; Han MY; An WS; Kim SH; Kim JC. Effects of AST-120 on muscle health and quality of life in chronic kidney disease patients: results of RECOVERY study. J Cachexia Sarcopenia Muscle. 2022: 1;13(1):397–408. 46. Rao NS; Chandra A; Saran S; Lohiya A. Ultrasound for thigh muscle thickness is a valuable tool in the diagnosis of sarcopenia in Indian patients with predialysis chronic kidney disease. Osteoporos Sarcopenia. 2022 Jun;8(2):80–5. 47. Shin J; Hwang JH; Han M. et al. Phase angle as a marker for muscle health and quality of life in patients with chronic kidney disease. Clinical Nutrition. 2022 Aug 1;41(8):1651–9. 48. De Souza VA; Oliveira D; Barbosa SR et al. Sarcopenia in patients with chronic kidney disease not yet on dialysis: Analysis of the prevalence and associated factors. PLoS One. 2017 Apr 1;12(4). 49. Wilkinson TJ; Miksza J; Yates T et al. Association of sarcopenia with mortality and end-stage renal disease in those with chronic kidney disease: a UK Biobank study. J Cachexia Sarcopenia Muscle. 2021; 12:586e98. 50. Yoshimura Y; Wakabayashi H; Nagano F; Bise T; Shimazu S; Shiraishi A. Elevated Creatinine-Based Estimated Glomerular Filtration Rate is Associated with Increased Risk of Sarcopenia, Dysphagia, and Reduced Functional Recovery after Stroke. Journal of Stroke and Cerebrovascular Diseases. 2021 Feb 1;30(2). 51. Lin YL; Wang CH; Tsai JP et al. A Comparison of SARC-F, Calf Circumference, and Their Combination for Sarcopenia Screening among Patients Undergoing Peritoneal Dialysis. Nutrients. 2022 Mar 1;14(5). 113 52. Androga L. et al.: Sarcopenia, Obesity, and Mortality. Kidney International Reports (2017) 2, 201–211. 53. Bichels AV; Cordeiro AC; Avesani CM et al. Muscle mass assessed by computed tomography at the third lumbar vertebra predicts patient survival in chronic kidney disease. J Ren Nutr. 2021; 31:342e50. 54. Brar RS; Whitlock RH; Komenda PVJ et al. Provider perception of frailty is associated with dialysis decision making in patients with advanced CKD. Clin J Am Soc Nephrol. 2021; 16:552e9. 55. Kruse NT; Buzkova P; Barzilay JI et al. Association of skeletal muscle mass, kidney disease and mortality in older men and women: the cardiovascular health study. Aging. 2020; 12:21023e36. 56. Jung H; Choi IY; Shin DW et al. Association between physical performance and incidence of end-stage renal disease in older adults: a national wide cohort study. BMC Nephrol. 2021; 22:85. 57. Lin T-Y; Wu M-Y; Chen H-S; Hung S-C; Lim P-S. Development and validation of a multifrequency bioimpedance spectroscopy equation to predict appendicular skeletal muscle mass in hemodialysis patients. Clin Nutr. 2021; 40:3288e95. 58. Pereira RA; Cordeiro AC; Avesani CM et al. Sarcopenia in chronic kidney disease on conservative therapy: prevalence and association with mortality. Nephrol Dial Transplant. 2015; 30:1718e25. 59. Roshanravan B; Robinson-Cohen C; Patel KV et al. Association between physical performance and all-cause mortality in CKD. J Am Soc Nephrol. 2013; 24:822e30. 60. Weng S-C; Chen Y-C; Hsu C-Y; Lin C-S; Tarng D-C; Lin S-Y. Impacts of heart failure and physical performance on long-term mortality in old patients with chronic kidney disease. Front Cardiovasc Med. 2021;8. 61. Treuil M; Mahmutovic M; Di Patrizio P; Nguyen-Thi P; Quilliot Q et al. Assessment of dynapenia and undernutrition in primary care, a systematic screening study in community medicine. Clin Nutr ESPEN. 2023 Oct: 57:561568. 62. Ohinata H; Yun S; Miyajima N; Yuki M. Association between dynapenia and multimorbidity: A systematic review. Ann Geriatr Med Res. 2024 Apr 24. 114 63. Corrêa HL; Rosa TS; Dutra mT et al. Association between dynapenic abdominal obesity and inflammatory profile in diabetic older community-dwelling patients with end-stage renal disease. Exp Gerontol. 2021: 146:111243. 64. Hayashi H; Izumiya Y; Hayashi O; Ichii M; Tsujimoto Y; Yoshiyama M. Dynapenia is an independent predictor of cardio-cerebrovascular events in patients undergoing hemodialysis. Heart Vessels. 2022 Jun;37(6):1066-1074. 65. Yoshikoshi S; Yamamoto S; Suzuki Y. Associations between dynapenia, cardiovascular hospitalizations, and all-cause mortality among patients on haemodialysis. J Cachexia Sarcopenia Muscle. 2022 Oct;13(5):2417-2425. 66. Souza LP; Martins CA; Cattafesta M; Santos-Neto ET; Salaroli LB. Waist-toheight ratio and dynapenic abdominal obesity in users of hemodialysis services. Nutr Metab Cardiovasc Dis. 2023 Aug;33(8):1583-1590. 67. Guida B; Di Maro M; Di Lauro M. et al. Identification of sarcopenia and dynapenia in CKD predialysis patients with EGWSOP2 criteria: An observational, cross-sectional study. Nutrition. 2020: 78:110815. doi: 10.1016/j.nut.2020.110815. 68. THE WHOQOL GROUP. The World Health Organization quality of life assessment (WHOQOL): position paper from the World Health Organization. Social science & medicine, v. 41, n. 10, p. 1403-1409, 1995. 69. CDC. Health-related quality of life (HRQOL) [cited 2020 July 24]. Available from: https://www.cdc.gov/hrqol/index.htm 70. Valderrabano F; Jofre R; Lopez-Gomez JM. Quality of life in end-stage renal disease patients. American journal of kidney diseases : the official journal of the National Kidney 10.1053/ajkd.2001.26824. Foundation. 2001 Sep;38(3):443-64. doi: 71. Piillips L; Davies SJ; White E. Health-related quality of life assessment in endstage renal failure. NT Research. 2001;6(3):658-670. 72. Perlman RL; Finkelstein FO; Liu L; et al. Quality of life in chronic kidney disease (CKD): a crosssectional analysis in the Renal Research Institute-CKD study. American journal of kidney diseases: the official journal of the National Kidney Foundation. 2005 Apr;45(4):658-66. doi:10.1053/j.ajkd.2004.12.021. 73. Porter A; Fischer MJ; Brooks D; et al. Quality of life and psychosocial factors in African Americans with hypertensive chronic kidney disease. Translational 115 research : the journal of laboratory and clinical medicine. 2012 Jan;159(1):4-11. doi: 10.1016/j.trsl.2011.09.004. PubMed PMID: 22153804. 74. Alhaji MM; Tan J; Hamid MRA; et al. Determinants of quality of life as measured with variants of SF-36 in patients with predialysis chronic kidney disease. Saudi medical journal. 2018;39(7):653. 75. Porter AC; Lash JP; Xie D; et al. Predictors and outcomes of health–related quality of life in adults with CKD. Clinical Journal of the American Society of Nephrology. 2016;11(7):1154-1162. 76. Nguyen NT, Cockwell P, Maxwell AP, et al. Chronic kidney disease, healthrelated quality of life and their associated economic burden among a nationally representative sample of community dwelling adults in England. PloS one. 2018;13(11):e0207960. 77. Chin HJ, Song YR, Lee JJ, et al. Moderately decreased renal function negatively affects the health-related quality of life among the elderly Korean population: a population-based study. Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association - European Renal Association. 2008 Sep;23(9):2810-7. doi: 10.1093/ndt/gfn132. 78. Wyld MLR, Morton RL, Clayton P, et al. The impact of progressive chronic kidney disease on health-related quality-of-life: a 12-year community cohort study. Qual Life Res. 2019 Aug;28(8):2081-2090. doi: 10.1007/s11136-01902173-1. 79. WARE, J. E.; SHERBOURNE, C. D. The MOS 36-Item Short-Form Health Survey (SF-36): I. conceptual framework and item selection. Med. Care, v. 30, p. 473-483, 1992. 80. HAYES, V. et al. The SF-36 Health Survey Questionnaire: Is it Suitable for use with Older Adults?. Age and Ageing, v. 24, n. 2, p. 1203125, 1995. 81. CICONELLI, R. M. et al. Tradução para a língua portuguesa e validação do questionário genérico de avaliação de qualidade de vida SF-36 (Brasil SF 36). Rev Bras Reumatol. v. 39, n. 3, p. 143-50, 1999. 82. Euroqol. EQ5D [cited 2020 14 July]. Available from: https://euroqol.org 83. Cella DF. Methods and problems in measuring quality of life. Supportive care in cancer: oficial journal of the Multinational Association of Supportive Care in Cancer. 1995 Jan;3(1):11-22. doi:10.1007/bf00343916. [cited 2020 14 July]. Available 116 84. KDQOL-36 https://www.rand.org/healthcare/surveys_tools/kdqol.html 85. Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis. Canadian Erythropoietin Study from: Group. BMJ. 10.1136/bmj.300.6724.573. | pt_BR |
dc.type.degree | Doutorado | pt_BR |
Aparece nas coleções: | Tese (PPGANS) |
Arquivo | Descrição | Tamanho | Formato | |
---|---|---|---|---|
Tese Tarcisio versão final.pdf Until 2025-12-17 | Tese - Tarcisio Santana | 3,07 MB | Adobe PDF | Visualizar/Abrir Solicitar uma cópia |
3_DOCUMENTOS_PARA_DEFESA_DE_TARCISIOpdf.pdf | 574,69 kB | Adobe PDF | Visualizar/Abrir | |
3_DOCUMENTOS_PARA_DEFESA_DE_TARCISIOpdf 2.pdf | 236,14 kB | Adobe PDF | Visualizar/Abrir |
Os itens no repositório estão protegidos por copyright, com todos os direitos reservados, salvo quando é indicado o contrário.